Prediction of fatal intracranial hemorrhage in patients with acute myeloid leukemia

Annals of Oncology

Volumn 20, Issue 6, 2009, Pages 1100-1104

  Chen, C Y ^a   Tai, C H ^a   Tsay, W ^a   Chen, P Y ^a   Tien, H F ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acute myeloid leukemia; Cerebral hemorrhage; Prognosis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYTARABINE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BASAL GANGLION HEMORRHAGE; BRAIN HEMORRHAGE; BRAIN STEM BLEEDING; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RELAPSE; CEREBELLUM HEMORRHAGE; CRANIOTOMY; DISEASE ASSOCIATION; DRUG MEGADOSE; EPIDURAL HEMORRHAGE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRAPARENCHYMAL HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; PROTHROMBIN TIME; REFRACTORY PERIOD; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; SUPRATENTORIUM HEMORRHAGE;

EID: 66149086144     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn755     Document Type: Article

References (34)

1. Rogers LR. Cerebrovascular complications in patients with cancer. Semin Neurol 2004; 24: 453-460.
2. Rogers LR. Cerebrovascular complications in cancer patients. Neurol Clin 2003; 21: 167-192.
3. Quinones-Hinojosa A, Gulati M, Singh V, Lawton MT. Spontaneous intracerebral hemorrhage due to coagulation disorders. Neurosurg Focus 2003; 15: E3.
4. Yamauchi K, Umeda Y. Symptomatic ICH haemorrhage in acute nonlymphoblastic leukaemia: Analysis of CT and autopsy findings. J Neurol 1997; 244: 94-100.
5. McCormick WF, Rosenfield DB. Massive brain hemorrhage: A review of 144 cases and an examination of their causes. Stroke 1973; 4: 946-954.
6. Foss B, Bruserud O. Platelet functions and clinical effects in acute myelogenous leukemia. Thromb Haemost 2008; 99: 27-37.
7. Arbuthnot C, Wilde JT. Haemostatic problems in acute promyelocytic leukaemia. Blood Rev 2006; 20: 289-297.
8. Lengfelder E, Saussele S, Weisser A et al. Treatment concepts of acute promyelocytic leukemia. Crit Rev Oncol Hematol 2005; 56: 261-274.
9. Rodeghiero F, Avvisati G, Castaman G et al. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75: 2112-2117.
10. Falanga A, Rickles FR. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16: 463-482.
11. Visani G, Gugliotta L, Tosi P et al. All-trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia. Eur J Haematol 2000; 64: 139-144.
12. Di Bona E, Avvisati G, Castaman G et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 2000; 108: 689-695.
13. Heckman KD, Weiner GJ, Davis CS et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol 1997; 15: 1143-1149.
14. Rebulla P, Finazzi G, Marangoni F et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997; 337: 1870-1875.
15. Tinmouth AT, Freedman J. Prophylactic platelet transfusions: Which dose is the best dose? A review of the literature. Transfus Med Rev 2003; 17: 181-193.
16. Sensebe L, Giraudeau B, Bardiaux L et al. The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. Blood 2005; 105: 862-864.
17. Kim H, Lee JH, Choi SJ et al. Analysis of fatal ICH hemorrhage in 792 acute leukemia patients. Haematologica 2004; 89: 622-624.
18. Kim H, Lee JH, Choi SJ et al. Risk score model for fatal ICH hemorrhage in acute leukemia. Leukemia 2006; 20: 770-776.
19. Bleggi-Torres LF, de Medeiros BC, Werner B et al. Neuropathological findings after bone marrow transplantation: An autopsy study of 180 cases. Bone Marrow Transplant 2000; 25: 301-307.
20. Nevo S, Vogelsang GB. Acute bleeding complications in patients after bone marrow transplantation. Curr Opin Hematol 2001; 8: 319-325.
21. Manno EM, Atkinson JL, Fulgham JR, Wijdicks EF. Emerging medical and surgical management strategies in the evaluation and treatment of intracerebral hemorrhage. Mayo Clin Proc 2005; 80: 420-433.
22. Ferro JM. Update on intracerebral haemorrhage. J Neurol 2006; 253: 985-999.
23. Vahdat L, Maslak P, Miller WH Jr et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84: 3843-3849.
24. Nowacki P, Zdziarska B, Fryze C, Urasinski I. Co-existence of thrombocytopenia and hyperleukocytosis ('critical period') as a risk factor of haemorrhage into the central nervous system in patients with acute leukaemias. Haematologia (Budap) 2002; 31: 347-355.
25. Chang MC, Chen TY, Tang JL et al. Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: No impact on early mortality and ICH hemorrhage. Am J Hematol 2007; 82: 976-980.
26. Fang HY, Lin CY, Ko WJ. Hematology and coagulation parameters predict outcome in Taiwanese patients with spontaneous intracerebral hemorrhage. Eur J Neurol 2005; 12: 226-232.
27. Kawanami T, Kurita K, Yamakawa M et al. Cerebrovascular disease in acute leukemia: A clinicopathological study of 14 patients. Intern Med 2002; 41: 1130-1134.
28. Minette SE, Kimmel DW. Subdural hematoma in patients with systemic cancer. Mayo Clin Proc 1989; 64: 637-642.
29. Jourdan E, Dombret H, Glaisner S et al. Unexpected high incidence of ICH subdural haematoma during intensive chemotherapy for acute myeloid leukaemia with a monoblastic component. Br J Haematol 1995; 89: 527-530.
30. McClelland S III, Won EK, Lam CH. Utilization of recombinant activated factor VII for ICH hematoma evacuation in coagulopathic nonhemophilic neurosurgical patients with normal international normalized ratios. Neurocrit Care 2007; 7: 136-139.
31. Zver S, Andoljsek D, Cernelc P. Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. Eur J Haematol 2004; 72: 455-456.
32. Alimoghaddam K, Ghavamzadeh A, Jahani M. Use of Novoseven for arsenic trioxide-induced bleeding in PML. Am J Hematol 2006; 81: 720.
33. Mayer SA, Brun NC, Broderick J et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2005; 36: 74-79.
34. Diringer MN, Skolnick BE, Mayer SA et al. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke 2008; 39: 850-856.